ESOPJun 17, 2026, 05:31 PM
Acrivon Therapeutics Stockholders Approve Amended 2022 Equity Plan
AI Summary
Acrivon Therapeutics, Inc. announced that its stockholders approved the Amended and Restated 2022 Equity Incentive Plan at the 2026 annual meeting. This plan increases the aggregate number of shares available for equity awards by 3,000,000, bringing the total to 8,606,723 shares, with automatic annual increases. Additionally, stockholders elected Michael Tomsicek and Charles Baum as Class I directors and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Key Highlights
- Stockholders approved the Acrivon Therapeutics, Inc. Amended and Restated 2022 Equity Incentive Plan.
- The Amended and Restated 2022 Plan increases the aggregate share reserve by 3,000,000 shares to 8,606,723 shares.
- The share reserve will automatically increase annually by 5% of fully diluted shares through 2032.
- Michael Tomsicek, M.B.A. and Charles Baum, M.D., Ph.D. were elected as Class I directors until the 2029 Annual Meeting.
- Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026.
Price Impact
More from ACRV